MetaADEDB 2.0 @ LMMD
Opipramol
(YNZFUWZUGRBMHL-UHFFFAOYSA-N)
Structure
SMILES
OCCN1CCN(CC1)CCCN1c2ccccc2C=Cc2c1cccc2
Type(s)
Investigational
ATC code(s)
N06AA05
Molecular Formula:
C23H29N3O
Molecular Weight:
363.496
Log P:
3.2493
Hydrogen Bond Acceptor:
3
Hydrogen Bond Donor:
1
TPSA:
29.95
CAS Number(s):
315-72-0
Synonym(s)
1.
Opipramol
2.
Insidon
3.
Opipramol Hydrochloride
4.
Hydrochloride, Opipramol
External Link(s)
MeSHD009888
PubChem Compound9417
BindingDB50170636
ChEBI94614
CHEMBLCHEMBL370753
DrugBankDB12930
DrugCentral1993
KEGGdr:D08297
Therapeutic Target DatabaseD0D7TB
ZINC21981303
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1AbuseOFFSIDES
2AcneOFFSIDES
3AgraphiaOFFSIDES
4Alanine Aminotransferase IncreasedOFFSIDES
5Antidepressant drug level above therapeuticOFFSIDES
6Application site pruritusOFFSIDES
7Application site rashOFFSIDES
8AuraOFFSIDES
9Bacteria urine identifiedOFFSIDES
10Bile Duct StenosisOFFSIDES
11Bile duct stent insertionOFFSIDES
12Bipolar I disorderOFFSIDES
13BlepharoptosisOFFSIDES
14Blood creatinine decreasedOFFSIDES
15Blood glucose decreasedOFFSIDES
16Blood sodium increasedOFFSIDES
17BronchopneumoniaOFFSIDES
18Bulbar palsyOFFSIDES
19Burning sensationOFFSIDES
20Chemotherapeutic drug level increasedOFFSIDES
21Cold sweatOFFSIDES
22Concomitant disease progressionOFFSIDES
23Congenital heart diseaseOFFSIDES
24CystOFFSIDES
25DiplopiaOFFSIDES
26Disease ProgressionOFFSIDES
27Disruptive, Impulse Control, and Conduct Disorders2098752CTD
28DrowsinessOFFSIDES
29Drug administration errorOFFSIDES
30Drug withdrawal headacheOFFSIDES
31Duodenal sphincterotomyOFFSIDES
32Dysthymic DisorderOFFSIDES
33Emotional distressOFFSIDES
34FatigueOFFSIDES
35Fatty LiverOFFSIDES
36Gamma-Glutamyltransferase IncreasedOFFSIDES
37Gastrointestinal sounds abnormalOFFSIDES
38Granuloma AnnulareOFFSIDES
39HepatotoxicityOFFSIDES
40HyperkeratosisOFFSIDES
41Impaired driving abilityOFFSIDES
42LeukoaraiosisOFFSIDES
43Limb discomfortOFFSIDES
44MacrocytosisOFFSIDES
45Mental disorders16856516CTD
46Multiple SclerosisOFFSIDES
47Multiple drug overdose intentionalOFFSIDES
48OsteomyelitisOFFSIDES
49OsteoporosisOFFSIDES
50Performance status decreasedOFFSIDES
51Pericardial effusionOFFSIDES
52Psychomotor Agitation2098752CTD
53SoporOFFSIDES
54TinnitusOFFSIDES
55Transaminases increasedOFFSIDES
56Visual disturbanceOFFSIDES
57Weight GainOFFSIDES
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120239

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.